These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Prenatal prediction of spinal muscular atrophy in Chinese. Lin SP; Chang JG; Jong YJ; Yang TY; Tsai CH; Wang NM; Li H; Hsieh-Li HM; Hu CJ Prenat Diagn; 1999 Jul; 19(7):657-61. PubMed ID: 10419615 [TBL] [Abstract][Full Text] [Related]
12. Transmission ratio distortion in the spinal muscular atrophy locus: data from 314 prenatal tests. Botta A; Tacconelli A; Bagni I; Giardina E; Bonifazi E; Pietropolli A; Clementi M; Novelli G Neurology; 2005 Nov; 65(10):1631-5. PubMed ID: 16301493 [TBL] [Abstract][Full Text] [Related]
13. Prenatal prediction in families with autosomal recessive proximal spinal muscular atrophy (5q11.2-q13.3): molecular genetics and clinical experience in 109 cases. Wirth B; Rudnik-Schöneborn S; Hahnen E; Röhrig D; Zerres K Prenat Diagn; 1995 May; 15(5):407-17. PubMed ID: 7644431 [TBL] [Abstract][Full Text] [Related]
14. Spinal muscular atrophy: antisense oligonucleotide therapy opens the door to an integrated therapeutic landscape. Wood MJA; Talbot K; Bowerman M Hum Mol Genet; 2017 Oct; 26(R2):R151-R159. PubMed ID: 28977438 [TBL] [Abstract][Full Text] [Related]
15. Evaluating Benefit-risk Decision-making in Spinal Muscular Atrophy: A First-ever Study to Assess Risk Tolerance in the SMA Patient Community. Cruz R; Belter L; Wasnock M; Nazarelli A; Jarecki J Clin Ther; 2019 May; 41(5):943-960.e4. PubMed ID: 31056304 [TBL] [Abstract][Full Text] [Related]
16. Bridging the Gap: Gene Therapy in a Patient With Spinal Muscular Atrophy Type 1. Costamagna G; Govoni A; Wise A; Corti S Neurology; 2022 Nov; 99(21):952-956. PubMed ID: 36319109 [TBL] [Abstract][Full Text] [Related]
17. New and Developing Therapies in Spinal Muscular Atrophy: From Genotype to Phenotype to Treatment and Where Do We Stand? Chen TH Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32392694 [TBL] [Abstract][Full Text] [Related]
18. Moving towards treatments for spinal muscular atrophy: hopes and limits. Wirth B; Barkats M; Martinat C; Sendtner M; Gillingwater TH Expert Opin Emerg Drugs; 2015 Sep; 20(3):353-6. PubMed ID: 25920617 [TBL] [Abstract][Full Text] [Related]
19. Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy. Zhou H; Meng J; Malerba A; Catapano F; Sintusek P; Jarmin S; Feng L; Lu-Nguyen N; Sun L; Mariot V; Dumonceaux J; Morgan JE; Gissen P; Dickson G; Muntoni F J Cachexia Sarcopenia Muscle; 2020 Jun; 11(3):768-782. PubMed ID: 32031328 [TBL] [Abstract][Full Text] [Related]